Oric Pharmaceuticals' Enozertinib Shows 88% Response Rate in EGFR Lung Cancer Study

Oric Pharmaceuticals NASDAQ: ORIC reported updated Phase 1b data for enozertinib in previously untreated patients with advanced non-small cell lung cancer (NSCLC) carrying atypical EGFR mutations, highlighting systemic and intracranial responses in a cohort with a high prevalence of baseline brain metastases.

MarketBeat • 28 minutes ago

ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial

In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and 70% confirmed intracranial ORR, with multiple intracranial complete responses

GlobeNewsWire • 10 hours ago

ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026

Preclinical data highlight potential advantages of targeting PRC2 via EED over EZH2, including the emergence of resistance mutations to EZH2 inhibitors like mevrometostat and against which the EED inhibitor rinzimetostat maintained effectiveness

GlobeNewsWire • 10 hours ago

ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026

Conference call and webcast to take place on Friday, October 23, 2026, at 8:00 a.m. ET Event to feature Dr. Joshua Sabari to discuss enozertinib clinical data and the potential of enozertinib to treat first-line NSCLC patients with EGFR atypical mutations SOUTH SAN FRANCISCO, Calif.

GlobeNewsWire • Oct 19, 2026

ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development

ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target Cancer Research UK to fully fund, sponsor, design, and execute CTA-enabling studies and Phase 1/2 clinical development ORIC retains exclusive option to reacquire rights to ORIC-259 following Phase 1/2 data SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced an agreement with Cancer Research UK, one of the world's largest funders of cancer research, to advance a potential first-in-class CIP2A-targeted therapy into clinical development.

GlobeNewsWire • Oct 5, 2026

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 1, 2026 (the “Grant Date”), ORIC granted a total of 161,550 non-qualified stock options and 26,850 restricted stock units to six new non-executive employees who began their employment with ORIC in September 2026.

GlobeNewsWire • Oct 2, 2026

ORIC Pharmaceuticals, Inc. (ORIC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

ORIC Pharmaceuticals, Inc. (ORIC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 16, 2026

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in September:

GlobeNewsWire • Sep 2, 2026

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates

Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1 Anticipate rinzimetostat program update in 2H 2026 and enozertinib clinical updates in 2H 2026 ahead of potential initiation of a registrational trial Cash and investments of approximately $388 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readout from first Phase 3 trial for rinzimetostat SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today reported financial results and provided operational updates for the quarter ended June 30, 2026.

GlobeNewsWire • Aug 3, 2026

ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen The Bull Case

ORIC Pharmaceuticals advances rinzimetostat into the global Phase 3 Himalayas-1 trial for mCRPC, with full global rights and royalty-free economics. ORIC's $419.7M cash position funds operations into 2H 2028, supporting pivotal trial readouts while minimizing dilution via strategic partnerships and disciplined capital allocation. Rinzimetostat's value is enhanced by a unique royalty-free license and free darolutamide supply from Bayer, maximizing potential post-approval returns.

Seeking Alpha • Jul 21, 2026